AI Engines For more Details: Perplexity Kagi Labs You
Peripheral Vascular Disorders: Moxisylyte hydrochloride is indicated for the treatment of peripheral vascular disorders, including peripheral artery disease (PAD) and Raynaud's phenomenon. These conditions are characterized by reduced blood flow to the extremities, leading to symptoms such as pain, numbness, and coldness in the hands and feet. Moxisylyte hydrochloride helps dilate blood vessels, improving blood flow and alleviating symptoms.
Intermittent Claudication: Intermittent claudication is a symptom of PAD characterized by leg pain or cramping that occurs during physical activity and improves with rest. Moxisylyte hydrochloride may help relieve symptoms of intermittent claudication by improving blood flow to the affected muscles, allowing individuals to walk longer distances without experiencing pain.
Erectile Dysfunction: Moxisylyte hydrochloride has also been used in the treatment of erectile dysfunction (ED). It works by dilating blood vessels in the penis, allowing for increased blood flow and improved erectile function. However, other medications such as phosphodiesterase type 5 (PDE5) inhibitors like sildenafil (Viagra) are more commonly used for ED treatment.
Ocular Disorders: Moxisylyte hydrochloride has been investigated for its potential use in the treatment of certain ocular disorders, including glaucoma and ocular hypertension. By dilating ocular blood vessels, moxisylyte hydrochloride may help improve blood flow to the eye and reduce intraocular pressure. However, further research is needed to determine its efficacy and safety for these indications.
Safety and Tolerability: Moxisylyte hydrochloride is generally well-tolerated, but like all medications, it may cause side effects in some individuals. Common side effects may include headache, dizziness, flushing, and gastrointestinal disturbances. Serious side effects such as hypotension (low blood pressure) and allergic reactions are rare but possible.
Drug Interactions: Moxisylyte hydrochloride may interact with other medications, particularly those that affect blood pressure or cardiovascular function. It's important to inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting moxisylyte hydrochloride therapy.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 0.4 | 0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.6 | 0 |
| Allergies | 0.9 | 1.5 | -0.67 |
| Allergy to milk products | 0.9 | 0.6 | 0.5 |
| Alzheimer's disease | 1.7 | 1.5 | 0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.4 | 0.6 | 1.33 |
| Ankylosing spondylitis | 1.4 | 0.6 | 1.33 |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Asthma | 1.2 | 1.7 | -0.42 |
| Atherosclerosis | 0.6 | 0.3 | 1 |
| Atrial fibrillation | 1.2 | 0.9 | 0.33 |
| Autism | 1.8 | 2.7 | -0.5 |
| Autoimmune Disease | 0.3 | 0.3 | 0 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 0.6 | 0.3 | 1 |
| Brain Trauma | 0.3 | 0.6 | -1 |
| Cancer (General) | 0.3 | 0.7 | -1.33 |
| Carcinoma | 0.9 | 0.6 | 0.5 |
| Celiac Disease | 0.6 | 1.8 | -2 |
| Cerebral Palsy | 1.1 | 0.3 | 2.67 |
| Chronic Fatigue Syndrome | 0.9 | 1 | -0.11 |
| Chronic Kidney Disease | 0.8 | 0.9 | -0.13 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.6 | -1 |
| Chronic Urticaria (Hives) | 0.3 | 0.6 | -1 |
| Cognitive Function | 0.6 | 0.3 | 1 |
| Colorectal Cancer | 1.5 | 0.6 | 1.5 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.6 | -0.6 | |
| COVID-19 | 1.5 | 2 | -0.33 |
| Crohn's Disease | 1.4 | 2 | -0.43 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.6 | -0.6 | |
| deep vein thrombosis | 0.3 | 0.3 | 0 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 2.4 | 2.6 | -0.08 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.3 | 0.3 | 0 |
| Endometriosis | 0.6 | 0.6 | 0 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.9 | 1.4 | -0.56 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 0.3 | 0.6 | -1 |
| Functional constipation / chronic idiopathic constipation | 0.9 | 0.8 | 0.13 |
| gallstone disease (gsd) | 0.3 | 0.6 | -1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | 0 |
| Generalized anxiety disorder | 0.6 | 0.9 | -0.5 |
| Gout | 0.8 | 0.3 | 1.67 |
| Graves' disease | 0.9 | 0.9 | 0 |
| Gulf War Syndrome | 1.1 | -1.1 | |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 1.1 | 1.4 | -0.27 |
| Heart Failure | 0.6 | 0.6 | 0 |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hypercholesterolemia (High Cholesterol) | 0.6 | -0.6 | |
| hyperglycemia | 0.7 | 1.4 | -1 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.9 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.7 | 1.5 | 0.13 |
| Hypothyroidism | 0.3 | 0.3 | 0 |
| Hypoxia | 0.9 | 0.3 | 2 |
| IgA nephropathy (IgAN) | 0.3 | 1 | -2.33 |
| Inflammatory Bowel Disease | 1.1 | 2.2 | -1 |
| Insomnia | 0.6 | 1.7 | -1.83 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 2.1 | 2 | 0.05 |
| ischemic stroke | 0.9 | 0.3 | 2 |
| Liver Cirrhosis | 1.6 | 2.6 | -0.63 |
| Long COVID | 1.8 | 1.8 | 0 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.5 | 0.6 | -0.2 |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.1 | 0.6 | -5 |
| ME/CFS without IBS | 0.6 | -0.6 | |
| Menopause | 0.1 | 0.3 | -2 |
| Metabolic Syndrome | 1.5 | 2.4 | -0.6 |
| Mood Disorders | 3.1 | 2 | 0.55 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.5 | 0.9 | 0.67 |
| Multiple system atrophy (MSA) | 0.8 | 0.3 | 1.67 |
| neuropathic pain | 1.2 | -1.2 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 1.8 | -2 |
| NonCeliac Gluten Sensitivity | 1.1 | 0.6 | 0.83 |
| Obesity | 3.2 | 2.9 | 0.1 |
| obsessive-compulsive disorder | 0.9 | 1.1 | -0.22 |
| Osteoarthritis | 0.3 | 0.9 | -2 |
| Osteoporosis | 0.6 | 0.9 | -0.5 |
| Parkinson's Disease | 2.3 | 1.5 | 0.53 |
| Polycystic ovary syndrome | 0.6 | 1.1 | -0.83 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.3 | 0.3 | |
| Primary sclerosing cholangitis | 0.7 | 0.7 | |
| Psoriasis | 0.9 | 0.9 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 0.9 | 0.67 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 2.2 | 1.4 | 0.57 |
| scoliosis | 0.6 | -0.6 | |
| Sjögren syndrome | 0.4 | 0.6 | -0.5 |
| Sleep Apnea | 0.6 | 0.3 | 1 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0 | 0 |
| Stress / posttraumatic stress disorder | 0.9 | 1.1 | -0.22 |
| Systemic Lupus Erythematosus | 0.9 | 0.9 | 0 |
| Tic Disorder | 0.3 | -0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.4 | 1.3 | 0.08 |
| Type 2 Diabetes | 1.5 | 2.1 | -0.4 |
| Ulcerative colitis | 1.2 | 1.7 | -0.42 |
| Unhealthy Ageing | 0.9 | 0.6 | 0.5 |
| Vitiligo | 0.9 | 0.6 | 0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
